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Abstract
Background: Breast cancer is a heterogenous disease that impacts racial/ethnic groups differently. Differences in genetic
composition, lifestyles, reproductive factors, or environmental exposures may contribute to the differential presentation of
breast cancer among Hispanic women.
Materials and Methods: A population-based study was conducted in the city of Santiago de Compostela, Spain. A total of
645 women diagnosed with operable invasive breast cancer between 1992 and 2005 participated in the study. Data on
demographics, breast cancer risk factors, and clinico-pathological characteristics of the tumors were collected. Hormone
receptor negative tumors were compared with hormone receptor postive tumors on their clinico-pathological
characteristics as well as risk factor profiles.
Results: Among the 645 breast cancer patients, 78% were estrogen receptor-positive (ER+) or progesterone receptor-
positive (PR+), and 22% were ER2&PR2. Women with a family history of breast cancer were more likely to have ER2&PR2
tumors than women without a family history (Odds ratio, 1.43; 95% confidence interval, 0.91–2.26). This association was
limited to cancers diagnosed before age 50 (Odds ratio, 2.79; 95% confidence interval, 1.34–5.81).
Conclusions: An increased proportion of ER2&PR2 breast cancer was observed among younger Spanish women with a
family history of the disease.
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Introduction
Breast cancer is a heterogenous disease with a range of
morphological phenotypes and histopathological subtypes with
distinct prognostic characteristics. It has been shown that women
diagnosed with estrogen receptor-positive (ER+)/progesterone
receptor-positive (PR+) tumors are more responsive to hormonal
treatment and have a better prognosis than those diagnosed with
estrogen receptor-negative (ER2)/progesterone receptor negative
(PR2) tumors, indicating etiologic heterogeneity of hormone-
receptor defined subtypes of breast cancer [1]. Consistently,
disparate risk factor profiles for breast cancer according to ER
andPRstatushavebeenreported[2];however,risksassociated with
family history of breast cancer do not seem to differ by receptor
status. In a recent study, Hines et al. [3] reported that family history
(FH) was significantly associated with an increased risk of both ER+
and ER2 breast cancers among non-Hispanic White (NHW)
women; however, among Hispanic women, having a family history
was associated with an increased risk of ER2 but not ER+e tumors,
indicating a distinct pattern of breast cancer among Hispanics.
Breast cancer impacts differently among each racial/ethnic
group in the United States [4,5,6,7]. Compared with NHW
women, Hispanic women have a lower incidence rate of breast
cancer; however, once diagnosed with this disease they are more
likely of dying from it. Such difference in survival may be
attributed to socioeconomic factors and/or differences in access to
screening and treatment [8]. However, studies [9,10] have found
that despite equal access to health care services, differences persist
in the presentation of Hispanic women with breast cancer
compared with NHW women, indicating a biologic basis for the
racial/ethnic differences. These differences may result from
racial/ethnic differences in genetic composition, lifestyles, repro-
ductive factors, or environmental exposures [10].
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defined by ER and PR status and assess the associations between
FH and ER and PR status in a series of female breast cancer
patients in Spain. To our knowledge, this study represents one of
the first studies to explore these relationships in a large population
of Spanish women.
Materials and Methods
Ethics
We obtained ethics approval for our study from the Comite ´
E ´tico de Investigacio ´n de Galicia associated with the Complexo
Hospitalario Universitario de Santiago from where all participants
were recruited. This study was conducted according to the Spanish
law including adherence to the Helsinki Principles of 1975, as
revised in 1983. Verbal informed consent, which was used in
majority of research studies at the time our study was initiated, was
specifically approved by the Comite ´E ´tico de Investigacio ´n de
Galicia. The information sheet was dated to document each
subject’s consent.
Study Population
As a part of the Breast Oncology Galician Network (BREO-
GAN), a population-based study was conducted in the city of
Santiago de Compostela, Spain within a geographically defined
health region that covers aproximately 500,000 inhabitants. The
study involved 663 women with operable invasive breast cancer
diagnosed and treated between April 1991 and December 2005 at
the Clinical University Hospital of Santiago de Compostela
(Santiago de Compostela, Spain) [11].
Data Collection
Risk factor and clinical information were collected in two ways.
Data on demographics, FH, reproductive history and other
variables were collected through a risk factor questionnaire.
Clinical and histopathological data were abstracted from medical
records by trained physicians. FH was defined as self-reported
history of breast cancer in any first- or second-degree relatives.
Information on FH was available for 645 of the 663 breast cancer
patients with known joint ER and PR status.
Clinico-Pathological Data
Immunohistochemistry (IHC) analyses on paraffin-embedded
material were performed to determine the status of ER, PR, MIB-
1, and P53. In every tumor, 4-mm histological sections were cut
and stained with hematoxylin and eosin for histopathological
examination according to the criteria of the World Health
Organization [12]. Histological grading was evaluated using the
Nottingham modification of the Bloom-Richardson system [13].
IHC analysis on paraffin-embedded material was performed using
antibodies for ER (clone 6F11, dilution 1:50, water bath;
Novocastra, Newcastle-upon- Tyne, UK), PR (clone PgR 636,
dilution 1:50, water bath; Dako, Glostrup, Denmark), MIB-1
(clone Ki-67, dilution 1:200, water bath; Dako), and p53 (clone
DO7, dilution 1:20, water bath; Novocastra). A peroxidase-
conjugated labeled dextran polymer was used as detection system
(EnVisionH, Peroxidase/DAB; Dako). Negative and positive
controls were concurrently run for all antibodies with satisfactory
results. Cells were considered immunopositive when diffuse or dot-
like nuclear staining was observed regardless of the intensity of the
staining; only nuclear immunoreactivity was considered specific.
The number of positive cells was counted by two different
observers independently. Whenever necessary, a consensus was
reached using a double-headed microscope. ER, PR and p53 were
considered positive when the percent of immunostained nuclei was
$10%. MIB-1 results were classified as low (#17%), moderate
(18–34%) or high ($35%).
Flow Cytometry and Karyometry. Flow cytometry analysis
was performed on fresh material from specimens obtained at the
time of surgery as previously reported [14]. The primary medical
use of flow cytometry is the indirect measurement of intracellular
DNA content. Measurement of the amount of DNA content in
tumor cells gives an indication of cell proliferation, as well as cells
with an abnormal amount of DNA, and thus may be of prognostic
value in cancer studies. SPF is defined as the percentage of cells in
phase S, in which the cell duplicates its DNA. DNA index (DI) is
defined as the ratio of the G0/G1 channel number of tumor cells
to the G0/G1 channel number of diploid cells. Tumor samples
were classified into two categories in relation to DI: diploid and
near diploid (DI=0.9621.15), aneuploid (DI.1.15 or DI,0.96).
Karyometry was carried out at a magnification of6400 using a
light microscope with an eyepiece equipped with a micrometer
grid. Details of procedures have been described in a previous
publication [11].
Statistical Analyses
Breast cancer was classified into two categories based on ER
and PR status: ER-positive or PR-positive (ER+/PR+) tumors
versus ER-negative and PR-negative (ER2&PR2) tumors. Case-
only analysis was conducted. Characteristics between breast
cancer subtypes were compared using univariate methods, i.e. t-
tests for continuous variables and x
2 tests for categorical variables
(fisher’s exact tests were used where sample sizes were small).
Similar statistical methods were used to compare cases with and
without a family history. Multivariate logistic regression was used
to estimate odds ratios (ORs), 95% confidence intervals (CIs), and
P values for associations between family history and breast cancer
subtypes while simultaneously controlling for age. Outcome
(dependent) variables were breast cancer subtypes defined by ER
and PR status as well as DI, and explanatory variable was family
history of breast cancer among any first- or second-degree relatives
(present vs. absent).
All statistical analyses were performed using the SAS 9.2
statistical software (SAS Institute Inc., Cary, NC). All reported test
significance levels (P values) were two-sided.
Results
A total of 645 breast cancer patients with known joint ER and
PR status were identified. Among them, 22% were ER2&PR2
and 78% were ER+/PR+ (Table 1). The age of these patients
ranged from 25 to 85 years, with a mean of 59 years. Compared to
women with ER+/PR+ tumors, women with ER2&PR2 tumors
were similar in age at diagnosis and tumor size, but were more
likely to have medullary carcinoma. ER2&PR2 tumors were also
more likely to be high grade, highly proliferative (based on S-phase
fraction and MIB-1 level), P53 positive, and aneuploid with larger
nuclear areas and perimeters; however, data on grade, MIB-1 and
P53 expression were missing for at least 106 patients.
We also compared tumor characteristis between breast cancer
patients with a positve family history and those without (Table 2).
Women with a family history were more likely to be diagnosed at
an earlier age and were more likely to be pre- or peri-menopausal,
but were less likely to have large tumors.
Table 3 shows the associations between select known breast
cancer risk factors and breast cancer subtypes defined by ER and
PR status. Age at menarche, parity, and menopausal status were
not significantly different by ER or PR status, after after adjusting
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were more likely to have ER2&PR2 tumors than women without
a family history (OR, 1.43; 95% CI, 0.91–2.26). Given the strong
association between family history and early onset of breast
cancer, we also evaluated this relationship stratified by age
(Table 4) and found that the observed association was limited to
women who were diagnosed before age 50 (OR, 2.79; 95% CI,
1.34–5.81). There was no association between family history and
hormone receptor status among cases diagnosed after age 50.
Results were similar when breast cancer subtypes were defined by
ER status alone. However, when breast caner subtypes were
defined by PR status alone, there was no significant association in
any of the age stratum.
Given our prior finding of DNA ploidy as an indepdent
prognostic factor for overall survival of breast cancer patients
[11], we further classified ER2&PR2 tumors by their DNA
index and evaluated the association of family history and these
tumor subtypes (Table 5). Family history was more pronouncedly
Table 1. Clinicopathological, Karyometric, and Immunohistochemical Characteristics of Breast Cancer Cases and by ER and PR
status.
All ER+/PR+ ER2&PR2
(N=645) (N=504) (N=141) PER2&PR2 vs. ER+/PR+
1
Age at diagnosis (years), 6SD
4 59614 59614 59616 0.67
Median6interquartile range 60621 60621 57624 0.66
,50, n (%) 467 (72%) 366 (73%) 101 (72%) 0.83
$50, n (%) 178 (28%) 138 (27%) 40 (28%)
Tumor size (cm), 6SD
4 3.563.2 3.463.3 3.662.5 0.48
Histological type
2, n (%) ,0.001
Invasive ductal carcinoma 531 (83%) 420 (84%) 111 (79%)
Invasive lobular carcinoma 57 (9%) 49 (10%) 8 (6%)
Invasive medullary carcinoma 21 (3%) 5 (1%) 16 (11%)
Other 34 (5%) 29 (6%) 5 (4%)
Axillary lymph node metastases
2, n (%) 338 (53%) 274 (55%) 64 (45%) 0.041
Microscopic grade
2, n (%) ,0.001
Grade I 117 (22%) 110 (25%) 7 (7%)
Grade II 305 (57%) 263 (61%) 42 (39%)
Grade III 117 (22%) 59 (14%) 58 (54%)
S-phase fraction, n (%) ,0.001
Low (#5%) 252 (39%) 224 (44%) 28 (20%)
Moderate (.5–10%) 248 (38%) 190 (38%) 58 (41%)
High (.10%) 145 (22%) 90 (18%) 55 (39%)
MIB-1
2, n (%) ,0.001
Low (#17%) 155 (30%) 148 (37%) 7 (6%)
Moderate (18–34%) 201 (38%) 167 (42%) 34 (28%)
High ($35%) 168 (32%) 86 (21%) 82 (67%)
P53 expression
2, n (%) 0.009
Negative 257 (62%) 207 (66%) 50 (51%)
Positive 158 (38%) 109 (34%) 49 (49%)
Ploidy
2, n (%) 0.049
Diploid & near-diploid 199 (31%) 167 (33%) 32 (23%)
Hyperploid 411 (64%) 309 (61%) 102 (72%)
Hypoploid 34 (5%) 27 (5%) 7 (5%)
Nuclear area
3 (mm
2), 6SD
4 104646 99642 121656 0.001
Perimeter
3(mm), 6SD
4 70614 68613 75617 0.002
Spherical
3 (%), 6SD
4 59615 60614 55617 0.014
Oval
3 (%), 6SD
4 31673 1 673 1 68 0.96
Cylindrical
3 (%), 6SD
4 11618 10619 14614 0.035
1Ps for categorical variables were estimated from x
2 tests. P for the comparison of median ages was esimated from Wilcoxon Rank-Sum test and Ps for other continuous
variables were estimated from t-tests.
2Histology, lymph node metastasis, grade, MIB1, P53 expression and DNA ploidy index, were unknown for 2, 7, 106, 121, 230 and 1 cases, respectively.
3Data on nuclear are, perimeter and DNA shape were available for only 353 cases.
4Mean 6standard deviation.
doi:10.1371/journal.pone.0029459.t001
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2.17; 95% CI, 0.99–4.74) than aneuploid ER2&PR2 tumors
(OR, 1.23; 95% CI, 0.73–2.08). Such difference in association
was also observed when limiting to cases diagnosed before age
50.
Discussion
In a population-based study of breast cancer patients from
Spain, we observed an increase in the proportion of ER2&PR2
breast cancer among women with a family history of the disease,
and such increase was limited to cases under 50 years of age.
The present study was conducted in Galicia, a region located in
the northwest part of Spain, whose history has been defined by
mass emigration especially to Latin America. Galicia has been the
Spanish region that contributed most to Latin America’s
emigration in the 1800s and 1900s [15]. In the United States,
Hispanics are a diverse and growing community that represents
12% of the US population [16]. Hispanic ethnicity, as defined by
the Office of Management and Budget in 1978, refers to persons
Table 2. Clinicopathological, karyometric, and immunohistochemical characteristics of breast cancer by family history.
No family history Family history
(n=520) (n=125) P
1
Age at diagnosis (years), 6SD
4 60614 54614 ,0.001
Median6interquartile range 61621 50623 ,0.001
,50, n (%) 117 (22%) 61 (49%) ,0.001
$50, n (%) 403 (78%) 64 (51%)
Tumor size (cm), 6SD
4 3.663.4 3.061.6 0.007
Histological type
2, n (%) 0.082
Invasive ductal carcinoma 421 (81%) 110 (89%)
Invasive lobular carcinoma 50 (10%) 7 (6%)
Invasive medullary carcinoma 16 (3%) 5 (4%)
Other 32 (6%) 2 (2%)
Axillary lymph node metastases
2, n (%) 270 (53%) 68 (54%) 0.76
Microscopic grade
2, n (%) ,0.13
Grade I 99 (23%) 18 (16%)
Grade II 232 (54%) 73(65%)
Grade III 95 (22%) 22 (19%)
S-phase fraction, n (%) 0.30
Low (#5%) 210 (40%) 42 (34%)
Moderate (.5–10%) 193 (37%) 55 (44%)
High (.10%) 117 (23%) 28 (22%)
MIB-1
2, n (%) 0.22
Low (#17%) 128 (31%) 27 (26%)
Moderate (18–34%) 164 (39%) 37 (35%)
High ($35%) 127 (30%) 41 (39%)
Ploidy
2, n (%) 0.78
Diploid & near-diploid 160 (31%) 39 (31%)
Hyperploid 330 (64%) 81 (65%)
Hypoploid 29 (6%) 5 (4%)
P53 expression
2, n (%) 0.089
Negative 203 (60%) 54 (71%)
Positive 136 (40%) 22 (29%)
Nuclear area
3 (mm
2), 6SD
4 105646 96644 0.18
Perimeter
3(mm), 6SD
4 70615 67613 0.11
Spherical
3 (%), 6SD
4 58615 63614 0.032
Oval
3 (%), 6SD
4 31673 0 67 0.37
Cylindrical
3 (%), 6SD
4 12619 769 0.005
1Ps for categorical variables were estimated from x
2 tests. P for the comparison of median ages was esimated from Wilcoxon Rank-Sum test and Ps for other continuous
variables were estimated from t-tests.
2Histology, lymph node metastasis, grade, MIB1, P53 expression and DNA ploidy index were unknown for 11, 48, 2, 7, 106, 121, 230 and 1 cases, respectively.
3Data on nuclear are, perimeter and DNA shape were available for only 353 cases.
4Mean 6standard deviation.
doi:10.1371/journal.pone.0029459.t002
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Spanish cultures. Under this definition, Hispanics are culturally
and genetically a heterogeneous group [17]. In Latin America,
each country has its own demographic and genetic structure, with
its own distinct migration history between regions. All Hispanics
are basically tri-hybrid, i.e., their ancestral populations being
European, African, and Native American with the European
contribution usually being the highest, although this varies to a
degree [18]. The fact that Galicia has been the European state
with the highest emigration to Latin America in the 1800s and
1900s makes Galicia a likely contributor of the European ancestry
to Hispanics in the United States. In addition, the Galician
population provides an interesting contrast group to Hispanics
from the San Luis Valley, Colorado in the United States, many of
whom self-identify as being of ‘‘Spanish origin’’ [19].
In general, Hispanic patients with breast cancer tend to have
ER-negative tumors more frequently than non-Hispanic white
women [20,21]. Using 1990 to 2001 data from 11 population-
based cancer registries that participated in the SEER program,
Dunnwald et al. [22] reported that 19% of non-Hispanic white
breast cancer cases and 26% of Hispanic white cases were
ER2&PR2 tumors. The 4-Corners Breast Cancer Study
examined women with a family history of breast cancer and
showed that Hispanic women had a higher incidence of triple-
negative breast cancer, whereas NHW women had a higher
incidence of postmenopausal hormone receptor–positive breast
cancer [3]. In this study, ER2&PR2 tumors were observed
among 22% of patients, a rate comparable to previous reports of
Hispanics in the United States [1,22]. In addition, our findings
that ER2&PR2 tumors were more likely to be high grade, highly
proliferative but had similar tumor size and less lymph node
involvement, supports the hypothesis that the presence or absence
of ER and PR represents distinct biological entities rather than
different stages in the natural history of the disease.
Family history of breast cancer is an important established risk
factor of the disease. Most previous studies [23] have found that a
positive family history of breast cancer seems to increase risk
similarly for ER+ and ER2 tumors and similarly for all ER/PR
subtypes. In the Multiethnic Cohort Study [1], a family history of
breast cancer was similary associated with breast cancer subtypes
defined by ER and PR status, with hazard ratios ranging from
1.63 to 1.91 after adjusting for race/ethnicity and other known risk
factors of breast cancer. However, Hines et al. [3] found different
associations between family history and risk of breast cancer
subtypes when examined in Hispanic women and non-Hispanic
white women separately, with ORs of 1.89 and 1.41 for ER+ and
ER2 breast cancer respectively among NHW women and 1.04
and 2.66 among Hispanics. Consequently, in the case-only
analysis, women with a family history were found to have a
Table 3. Association between select breast cancer risk factors
and hormone receptor status.
No f No f
ER2&PR2 vs.
ER+/PR+
ER+/PR+ ER2&PR2 OR (95% CI)
1 P
1
Age at menarche
#12 130 38 1.00
13–14 209 62 1.02 (0.65–1.63) 0.92
$15 155 40 0.90 (0.54–1.52) 0.70
Parity
Nulliparous 94 24 1.00
1–2 children 219 57 0.98 (0.57–1.68) 0.93
3+ children 162 42 1.03 (0.59–1.81) 0.92
Menopausal status
Premenopausal 108 32 1.00
Peri-menopausal 57 11 0.73 (0.33–1.61) 0.44
Postmenopausal 339 98 1.32 (0.64–2.74) 0.45
Family history
No 413 107 1.00
Yes 91 34 1.43 (0.91–2.26) 0.12
1Results were estimated from case-only logistic regressions with adjustment for
age at diagnosis.
doi:10.1371/journal.pone.0029459.t003
Table 4. Family history and breast cancer hormone receptor status by age at diagnosis.
ER2&PR2
vs. ER+/PR+ ER2 vs. ER+ PR2 vs. PR+
No f No f No f
ER+/PR+ tumors ER+ tumors PR+ tumors
/ER2&PR2 tumors
1 OR (95% CI)
2 P
2 /ER2 tumors
1 OR (95% CI)
2 P
2 /PR2 tumors
1 OR (95% CI)
2 P
2
Among ,50
years old
Family history
o 98/19 1.00 97/22 1.00 74/35 1.00
Yes 40/21 2.79 (1.34–5.81) 0.006 39/23 2.66 (1.32–5.39) 0.006 36/24 1.40 (0.72–2.72) 0.32
Among 50+
years old
Family history
No 315/88 1.00 310/98 1.00 228/153 1.00
Yes 51/13 0.91 (0.48–1.76) 0.79 50/15 0.95 (0.51–1.76) 0.87 38/20 0.79 (0.44–1.40) 0.42
1Subjects with missing information of ER, PR, or family history were removed from analyses.
2Results were estimated from case-only logistic regressions with adjustment for age at diagnosis.
doi:10.1371/journal.pone.0029459.t004
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women without a family history among Hispanics, but not among
NHWs. This obsevation among Hispanics was consistent with our
finding of an association between family history and breast cancer
receptor-defined subytpes among women from Spain. Further-
more, both Hines et al. [3] and our study found that results were
similar with or without adjusting for PR status, indicating possible
differential involvement of ER and PR in the etiology of the
disease, or, alternatively that the driving force in the association
with family history is ER status and PR status does not really play
a role above and beyond that of ER.
An increased risk associated with a positive family history may
be attributed to shared genetic factors and environmental
exposures. Both Hines et al. [3] and our study found that the
association between family history and receptor-negative tumors
was stronger among younger women indicates a more important
contribution of genetic factors to family history. Hence, the finding
of a higher proportion of receptor-negative tumors among women
with a family history than those without suggests that hormone-
receptor-positive and receptor-negative tumors have different
genetic components to their risks. In line with this notion, most
breast cancers that occur in women with germline BRCA1
mutations are ER2 and PR2 and younger BRCA1 carriers were
significantly more likely to develop an ER2 cancer compared with
older carriers [24]. Furthermore, breast cancer susceptibility loci
identified from genome-wide association studies were also found to
confer risk differentially for ER+ and ER2 breast cancers [25,26].
It is unclear why the association between family history and
breast cancer hormone receptor status was observed among
Hispanics, but not among NHWs. It is possible that genetic
susceptibility to breast cancer may differ among ethnic popula-
tions. Major differences in gene expression between Hispanics and
NHW have also been described [27]. Baumbach et al. [28]
presented genetic microarray analysis of 28 paraffin-embedded,
triple-negative breast cancer samples from Hispanic, white, and
black women. Ethnic-specific expression patterns were observed in
both tumor and normal tissue specimens. Significant differential
expression of DNA repair pathway genes was observed in tumor
samples from all 3 ethnic groups. In another study [29], the
gamma-aminobutyric acid A receptor, whose progenitor cells are
hypothesized to proliferate within the breast lobules during
pregnancy and then are progressively lost during breastfeeding,
was expressed at higher levels in Hispanic women compared with
age-matched white controls.
The contribution of BRCA mutations may be different among
Hispanic breast cancer patients. In a population-based multiethnic
series of female breast cancer patients [30], BRCA1 mutation was
prevalent in 3.5% of Hispanics but only 2.2% of non-Hispanic
whites, suggesting differential contribution of BRCA1 mutations to
familial breast cancers in Hispanic women. Novel sequence
variants in BRCA1 and BRCA2 have been found in Spanish
families with multiple cases of breast and ovarian cancer
[31,32,33]. Founder effects have been observed in the Galician
population for some genetic diseases, including BRCA1 in familial
breast cancer [34]. It has been shown that the BRCA1 mutation
A330G, which results in a Arg to Gly change at codon 71 (R71G),
could have a Galician origin [32,34]. This mutation has been
observed in families in diverse geographical locations (Spain,
Caribbean, France, United Kingdom) which all have a Spanish
origin, and it co-segregates with cancer in those families [35].
Families inheriting this mutation were not recently related, and
most of them can trace their history to the Spanish colonization
period, suggesting that the families studied shared a common
ancestry with BRCA1 A330G being a founder mutation of Spanish
origin. In the largest study of high-risk Hispanic families in the
United States [36], 185delAG, a founder mutation seen in ,1% of
individuals of Ashkenazi Jewish ancestry, was found to be the most
common deleterious BRCA mutation and share the same
haplotype as a reference Ashkenazi Jewish population. Haplotype
analyses of additional recurrent BRCA1 mutations also suggest
founder effects, with four of six mutations seen almost exclusively
in families with Latin American/Caribbean or Spanish ancestry.
Aneuploidy, the numerical chromosomal aberrations, is one of
the most common abnormalities in cancer [37]. It has been
suggested that numerical chromosome changes and ploidy shifts
are pathogenetically important rather than only epiphenomena in
carcinogenesis. The finding that the effect of FH was limited to
diploid or near diploid ER2&PR2 tumors suggests distinct
biological mechanisms linking family history to receptor-negative
tumors.
The present study has a number of limitations. First, we were
unable to collect detailed information of patients’ family, such as
the number of affected relatives and age at diagnosis of the affected
relatives. Second, we did not collect information on sibship size
such that risks of family history could be calculated with
adjustment for this potential confounder. We recognize the
potential implications of this missing piece of information. Third,
our definition of family history considered all first and second-
Table 5. Family history and breast cancer subtypes further stratified by DNA ploidy.
Diploid & near-diploid Aneuploid
No f ER2&PR2 ER2&PR2
ER+/PR+ tumors
1 N
1 OR (95% CI)
2 P
2 N
1 OR (95% CI)
2 P
2
Family history
No 413 21 1.00 86 1.00
Yes 91 11 2.17 (0.99–4.74) 0.053 23 1.23 (0.73–2.08) 0.43
Among ,50 years old
Family history
No 98 3 1.00 16 1.00
Yes 40 7 5.87 (1.43–24.06) 0.014 14 2.21 (0.97–5.00) 0.058
1Subjects with missing information of ER, PR, or family history were removed from analyses.
2Results were estimated from case-only logistic regressions with adjustment for age at diagnosis.
doi:10.1371/journal.pone.0029459.t005
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accurate for first-degree than second-degree relatives [38].
Therefore, more misclassification may have occurred, biasing
our estiamtes towards null. In addition, the lack of a cancer-free
control group may limit our ability to generalize these results to
the general population. Finally, even though we were able to
collect relevant clinic-pathological data of breast cancer providing
additional information to the literature, such data were only
available for a subset of our participating patients.
In conclusion, our analysis of a Hispanic population from Spain
demonstrates an increase in the proportion of ER2&PR2 breast
cancer among women with a family history of the disease, an
increase that was limited to cases under 50 years of age. Our
results also indicate that the driving force in breast cancer
etiological differences may be ER not PR status. These results
complement emerging evidence that relationships for genetic
susceptibility loci also vary by expression levels of markers in
tumors [39]. Our results support the view that there may be more
than one type of breast cancer from an etiological perspective, and
specifically support the hypothesis that hormone receptor negative
tumors may have different etiologies from hormone receptor
positive tumors.
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